Advertisement

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Peter Clark, MA, MD, FRCP: A Payer Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Amit Sanyal, MD: A Clinician’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement

Sep

01

Today In Oncology

Osimertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in EGFR/TP53-Mutated NSCLC

Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint

The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation

Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution

First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer

Advertisement

© 2026 HSP News Service, L.L.C.